PD176067 is a reversible and selective inhibitor of
fibroblast growth factor receptor tyrosine kinase, and was in preclinical development as an
angiogenesis inhibitor for the treatment of solid
tumors. A 14-day oral toxicity study of
PD176067 in young female rats (7 weeks old) was conducted at doses of 2.5, 5, and 10 mg/kg/day (15, 30, and 60 mg/m(2), respectively). Skeletal changes, and vascular and soft tissue mineralization were observed as primary
drug-related toxicities. To determine if these changes are specific to young, rapidly growing animals with increased vascular and osseous development,
PD176067 was administered to mature (11 months old) rats. Female rats received
PD176067 by gavage for 14 days at doses of 2.5, 5, and 10 mg/kg/day and necropsied on day 15. Clinical signs of toxicity were seen at > or =5 mg/kg and one death occurred
at 10 mg/kg. Physeal dysplasia (distal femur, proximal tibia, sternum) occurred in all
drug-treated animals and was characterized by dose-related increased thickness of the zones of chondrocyte proliferation and
hypertrophy, and marked thickening of the zone of ossification. Cartilage
hyperplasia was characterized by proliferation of chondrocytes along margins of the synchondrosis and subperiosteum of sternebrae. Serum
phosphorus levels increased 47% and 166% at 5 and 10 mg/kg, respectively. Mineralization of cardiac myocytes, aorta, various arteries, renal tubules, and gastric mucosa and muscularis was seen
at 10 mg/kg, and consistent with the presence of
calcium-
phosphorus deposition. Physeal changes occurred at similar plasma
PD176067 exposures in young and mature rats (AUC > or = 4.83 microg.hr/mL).
PD176067 produced morphologically similar lesions in young and adult rats.